Radiotherapy and chemoradiotherapy for postoperative recurrence in patients with esophageal squamous cell carcinoma
Cancer Medicine · 2024
DOI: 10.1002/cam4.70108 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Qing Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Integrated Care Management Center, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Neoplasm Recurrence, Local, Chemoradiotherapy, Esophageal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 2023 Clinical Research Fund, West China Hospital, Sichuan University, Youth Innovation Scientific Research Project of Sichuan Medical Association.
Abstract (Originalsprache)
Background
The optimal treatment for esophageal squamous cell carcinoma (ESCC) patients with postoperative recurrence remains controversial. We aimed to evaluate the effects of radiotherapy (RT) and chemoradiotherapy (CRT) on postoperative recurrence in ESCC patients.
Methods
Recurrence ESCC patients who received salvage RT and CRT from January 2015 to January 2019 were retrospectively reviewed. Post‐recurrence survival (PRS) and prognostic factors were evaluated by Kaplan–Meier and Cox proportional hazards models, respectively. Subgroup analyses were performed based on pathological lymph node (LN) status (negative/positive) to evaluate the differences in salvage treatments and toxic reaction.
Results
A total of 170 patients were enrolled, with a median age of 60 years (range 43–77). No significant difference was found in the median PRS between the salvage RT and CRT groups ( p > 0.05). Multivariate analysis revealed that TNM stage III and IV, macroscopic medullary type, and distant metastasis recurrence pattern were independent prognostic factors (all p < 0.05) for PRS. Salvage treatment was not associated with PRS ( p = 0.897). However, in patients with negative LN, CRT was associated with prolonged survival ( p = 0.043) and had no significant differences in toxic reactions compared to RT ( p = 0.924). In addition, RT showed better prognoses ( p = 0.020) and lower toxic reactions ( p = 0.030) than CRT in patients with positive LNs.
Conclusions
Based on prognosis and toxic reactions, ESCC recurrence patients with negative LNs could benefit from CRT, but RT should be recommended for patients with positive LNs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Integrated Care Management Center, West China Hospital, Sichuan University, Chengdu, China.
- Anesthesia Operation Center of West China Hospital/West China School of Nursing, Sichuan University, Chengdu, China.
- Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
- Department of Cardiothoracic Intensive Care Unit, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
- Department of Pathology, Nanchong Central Hospital, Nanchong, China.
- Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
ORCID-Profile: Dai-Yuan Ma, Kai-Yuan Jiang
Förderung
- 2023 Clinical Research Fund, West China Hospital, Sichuan University
- Youth Innovation Scientific Research Project of Sichuan Medical Association
Zitieren
APA
Liu, Q., Tu, X. H., Yu, R. X., Wen, H. Y., Guo, X. G., Ma, D. Y., Jiang, K. Y., & Tian, D. (2024). Radiotherapy and chemoradiotherapy for postoperative recurrence in patients with esophageal squamous cell carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.70108
Vancouver
Liu Q, Tu XH, Yu RX, Wen HY, Guo XG, Ma DY, et al. Radiotherapy and chemoradiotherapy for postoperative recurrence in patients with esophageal squamous cell carcinoma. Cancer Medicine. 2024. doi:10.1002/cam4.70108
BibTeX
@article{Liu2024,
author = {Liu, Qing and Tu, Xue-Hua and Yu, Rui-Xuan and Wen, Hong-Ying and Guo, Xiao-Guang and Ma, Dai-Yuan and Jiang, Kai-Yuan and Tian, Dong},
title = {Radiotherapy and chemoradiotherapy for postoperative recurrence in patients with esophageal squamous cell carcinoma},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70108}
}
EUVIMED